Clinical trial
A Dose Escalation Trial of an Intravitreal Injection of Sirna-027 in Patients…
NCT00363714 · Allergan, Industry · Completed
Key facts
| NCT number | NCT00363714 |
|---|---|
| Title | A Dose Escalation Trial of an Intravitreal Injection of Sirna-027 in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) |
| Lead sponsor | Allergan, Industry |
| Collaborators | Sirna Therapeutics Inc. Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Age-Related Macular Degeneration, Choroidal Neovascularization |
| Intervention type | Drug |
| Interventions | AGN211745 |
| Enrollment | 26 |
| Start date | Nov 1, 2004 |
| Primary completion | Apr 1, 2007 |
| Completion | Apr 1, 2007 |
| First posted | Aug 15, 2006 |
| Last update posted | Aug 18, 2008 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: